Skip to main content
Home
Issues
2024
November 2024 Vol 17, Payers' Guide to FDA Updates
2023
December 2023 Vol 16, Payers' Guide to FDA Updates
September 2023 Vol 16, Payers' Guide to FDA Updates
June 2023 - Vol 16 No 1
Issue Archive
Topics
Conference Correspondent
ESMO 2024 - Small Cell Lung Cancer
EHA 2024 – Wrap-Up: Myelodysplastic Syndrome
ASCO 2024 – Wrap-Up: Myelodysplastic Syndrome
Multimedia
Videos
Interview with the Innovators
Editorial Board
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Process
Advertising Policy
Subscribe
Home
Issues
2024
November 2024 Vol 17, Payers' Guide to FDA Updates
2023
December 2023 Vol 16, Payers' Guide to FDA Updates
September 2023 Vol 16, Payers' Guide to FDA Updates
June 2023 - Vol 16 No 1
Issue Archive
Topics
Conference Correspondent
ESMO 2024 - Small Cell Lung Cancer
EHA 2024 – Wrap-Up: Myelodysplastic Syndrome
ASCO 2024 – Wrap-Up: Myelodysplastic Syndrome
Multimedia
Videos
Interview with the Innovators
Editorial Board
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Process
Advertising Policy
Loretta Fala
Medical Writer
Medical writer
Authored Items
Jemperli (Dostarlimab) First Immunotherapy Approved for Recurrent or Advanced Mismatch Repair-Deficient Endometrial Cancer
Loretta Fala
December 2021 Twelfth Annual Payers' Guide
in
FDA Approvals
Ukoniq (Umbralisib) FDA Approved for Adults with Relapsed or Refractory Marginal-Zone Lymphoma or Follicular Lymphoman
Loretta Fala
December 2021 Twelfth Annual Payers' Guide
in
FDA Approvals
Tabrecta (Capmatinib) First FDA-Approved Drug for Metastatic NSCLC with MET Exon 14 Skipping Mutation
Loretta Fala
December 2021 Twelfth Annual Payers' Guide
in
FDA Approvals
Abecma (Idecabtagene Vicleucel) First-in-Class BCMA-Directed CAR T-Cell Therapy Approved for Relapsed or Refractory Multiple Myeloma
Loretta Fala
December 2021 Twelfth Annual Payers' Guide
in
FDA Approvals
Truseltiq (Infigratinib) New Targeted Therapy FDA Approved for Advanced or Metastatic Cholangiocarcinoma Harboring FGFR2 Alterations
Loretta Fala
December 2021 Twelfth Annual Payers' Guide
in
FDA Approvals
Skyrizi (Risankizumab-rzaa) a New Treatment Option Approved by the FDA for Patients with Moderate-to-Severe Plaque Psoriasis
Loretta Fala
2019 Payers' Guide Mid-Year Addendum
in
FDA Approvals
Balversa (Erdafitinib), First-in-Class FGFR Kinase Inhibitor, Approved for Patients with Metastatic Urothelial Carcinoma and FGFR Mutations
Loretta Fala
2019 Payers' Guide Mid-Year Addendum
in
FDA Approvals
Spravato (Esketamine) Nasal Spray First NMDA Receptor Antagonist Approved by the FDA for Adults with Treatment-Resistant Depression
Loretta Fala
2019 Payers' Guide Mid-Year Addendum
in
FDA Approvals
Cablivi (Caplacizumab-yhdp): First Targeted, Nanobody-Based Therapy Approved for Adults with Acquired Thrombotic Thrombocytopenic Purpura
Loretta Fala
2019 Payers' Guide Mid-Year Addendum
in
FDA Approvals
Tremfya (Guselkumab), a Novel One-Press Patient-Controlled Injection, Approved for Moderate-to-Severe Plaque Psoriasis
Loretta Fala
2019 Payers' Guide Mid-Year Addendum
in
FDA Approvals
,
Biosimilars
,
Dermatology
Doptelet (Avatrombopag) Receives FDA Approval for the Treatment of Patients with Chronic Immune Thrombocytopenia
Loretta Fala
2019 Payers' Guide Mid-Year Addendum
in
FDA Approvals
Zulresso (Brexanolone) First Drug Approved by the FDA Specifically for Postpartum Depression in Adults
Loretta Fala
2019 Payers' Guide Mid-Year Addendum
in
FDA Approvals
Tavalisse (Fostamatinib Disodium Hexahydrate) First Spleen Tyrosine Kinase Inhibitor Approved for Chronic Immune Thrombocytopenia
Loretta Fala
Web Exclusives
in
FDA Approvals
Daurismo (Glasdegib) Approved, in Combination with Low-Dose Cytarabine, for Newly Diagnosed Acute Myeloid Leukemia in Older Adults or Those Unfit for Intensive Chemotherapy
Loretta Fala
Web Exclusives
in
FDA Approvals
Lorbrena (Lorlatinib) Approved for the Treatment of Metastatic Non–Small-Cell Lung Cancer with ALK Mutation
Loretta Fala
Web Exclusives
in
FDA Approvals
Vizimpro (Dacomitinib) Approved for First-Line Treatment of Metastatic Non–Small-Cell Lung Cancer with EGFR Mutation
Loretta Fala
Web Exclusives
in
FDA Approvals
Yonsa (Fine-Particle Abiraterone Acetate) New Formulation Approved for Metastatic Prostate Cancer
Loretta Fala
Web Exclusives
in
FDA Approvals
Nuzyra (Omadacycline) Approved for the Treatment of Community-Acquired Bacterial Pneumonia or Acute Bacterial Skin and Skin Structure Infections
Loretta Fala
March 2019, Vol 12, Tenth Annual Payers' Guide
in
Payers' Guide
,
FDA Approvals
Olumiant (Baricitinib) Once-Daily Oral Drug Approved for the Treatment of Patients with Moderately to Severely Active Rheumatoid Arthritis
Loretta Fala
March 2019, Vol 12, Tenth Annual Payers' Guide
in
Payers' Guide
,
FDA Approvals
Ilumya (Tildrakizumab-asmn), Interleukin-23 Antagonist, Approved for the Treatment of Patients with Moderate-to-Severe Plaque Psoriasis
Loretta Fala
March 2019, Vol 12, Tenth Annual Payers' Guide
in
Payers' Guide
,
FDA Approvals
Tosymra (Sumatriptan) Nasal Spray Approved for the Acute Treatment of Migraine, with or without Aura
Loretta Fala
March 2019, Vol 12, Tenth Annual Payers' Guide
in
Payers' Guide
,
FDA Approvals
Erleada (Apalutamide) First Drug Approved by the FDA for Nonmetastatic Castration-Resistant Prostate Cancer
Loretta Fala
March 2019, Vol 12, Tenth Annual Payers' Guide
in
Payers' Guide
,
FDA Approvals
Libtayo (Cemiplimab-rwlc), a PD-1 Inhibitor, First Drug Approved by the FDA for Advanced Cutaneous Squamous-Cell Carcinoma
Loretta Fala
March 2019, Vol 12, Tenth Annual Payers' Guide
in
Payers' Guide
,
FDA Approvals
Xeljanz (Tofacitinib) Receives Expanded Indication, Becoming the First Oral JAK Inhibitor Approved for Ulcerative Colitis
Loretta Fala
March 2019, Vol 12, Tenth Annual Payers' Guide
in
Payers' Guide
,
FDA Approvals
Xermelo (Telotristat Ethyl), First-in-Class Tryptophan Hydroxylase Inhibitor, Approved for Carcinoid Syndrome Diarrhea
Loretta Fala
March 2018, Vol 11, Ninth Annual Payers' Guide
in
Payers' Guide
,
FDA Approvals
Tremfya (Guselkumab), First-in-Class IL-23 Blocker, Approved for the Treatment of Patients with Moderate-to-Severe Plaque Psoriasis
Loretta Fala
March 2018, Vol 11, Ninth Annual Payers' Guide
in
Payers' Guide
,
FDA Approvals
Siliq (Brodalumab) a New IL-17RA Antagonist Approved for Moderate-to-Severe Plaque Psoriasis
Loretta Fala
March 2018, Vol 11, Ninth Annual Payers' Guide
in
Payers' Guide
,
FDA Approvals
Nerlynx (Neratinib) First Extended Adjuvant Therapy Approved for HER2-Positive Breast Cancer
Loretta Fala
March 2018, Vol 11, Ninth Annual Payers' Guide
in
Payers' Guide
,
FDA Approvals
Idhifa (Enasidenib), First-in-Class IDH2 Inhibitor, Approved for Relapsed Acute Myeloid Leukemia with IDH2 Mutation
Loretta Fala
March 2018, Vol 11, Ninth Annual Payers' Guide
in
Payers' Guide
,
FDA Approvals
Gocovri (Amantadine) First Drug Approved for Dyskinesia in Patients with Parkinson’s Disease
Loretta Fala
March 2018, Vol 11, Ninth Annual Payers' Guide
in
Payers' Guide
,
FDA Approvals
Besponsa (Inotuzumab Ozogamicin) Approved for Adults with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
Loretta Fala
March 2018, Vol 11, Ninth Annual Payers' Guide
in
Payers' Guide
,
FDA Approvals
Yescarta (Axicabtagene Ciloleucel) Second CAR T-Cell Therapy Approved for Patients with Certain Types of Large B-Cell Lymphoma
Loretta Fala
March 2018, Vol 11, Ninth Annual Payers' Guide
in
Payers' Guide
,
FDA Approvals
Xeljanz/Xeljanz XR (Tofacitinib/Tofacitinib XR), an Oral JAK Inhibitor, Now Approved for Adults with Active Psoriatic Arthritis
Loretta Fala
March 2018, Vol 11, Ninth Annual Payers' Guide
in
Payers' Guide
,
FDA Approvals
Xadago (Safinamide), an Oral MAO-B Inhibitor, FDA Approved as Adjunctive Treatment for Patients with Parkinson’s Disease
Loretta Fala
March 2018, Vol 11, Ninth Annual Payers' Guide
in
Payers' Guide
,
FDA Approvals
Verzenio (Abemaciclib) a New CDK4/CDK6 Inhibitor Approved for HR-Positive, HER2-Negative Advanced or Metastatic Breast Cancer
Loretta Fala
March 2018, Vol 11, Ninth Annual Payers' Guide
in
Payers' Guide
,
FDA Approvals
Kymriah (Tisagenlecleucel) for Young Patients with Acute Lymphoblastic Leukemia: First FDA-Approved Gene Therapy
Loretta Fala
March 2018, Vol 11, Ninth Annual Payers' Guide
in
Payers' Guide
,
FDA Approvals
Kevzara (Sarilumab), a New IL-6 Receptor Antagonist, Approved for Active Rheumatoid Arthritis
Loretta Fala
March 2018, Vol 11, Ninth Annual Payers' Guide
in
Payers' Guide
,
FDA Approvals
Gazyva (Obinutuzumab) Approved for Patients with Rituximab-Refractory Follicular Lymphoma
Loretta Fala
March 2017, Vol 10, Eighth Annual Payers' Guide
in
Payers' Guide
,
FDA Approvals
Lartruvo (Olaratumab) a Novel First-Line Treatment Approved for Patients with Advanced Soft-Tissue Sarcoma
Loretta Fala
March 2017, Vol 10, Eighth Annual Payers' Guide
in
Payers' Guide
,
FDA Approvals
Soliqua 100/33 (Insulin Glargine plus Lixisenatide) Receives FDA Approval for Adults with Type 2 Diabetes
Loretta Fala
March 2017, Vol 10, Eighth Annual Payers' Guide
in
Payers' Guide
,
FDA Approvals
Yondelis (Trabectedin) Approved for the Treatment of Unresectable or Metastatic Soft-Tissue Sarcomas
Loretta Fala
March 2016, Vol 9, Seventh Annual Payers' Guide
in
Payers' Guide
Vyvanse (Lisdexamfetamine Dimesylate): First FDA-Approved Drug for the Treatment of Adults with Binge-Eating Disorder
Loretta Fala
March 2016, Vol 9, Seventh Annual Payers' Guide
in
Payers' Guide
Odomzo (Sonidegib), a Hedgehog Pathway Inhibitor, FDA Approved for the Treatment of Patients with Locally Advanced Basal-Cell Carcinoma
Loretta Fala
March 2016, Vol 9, Seventh Annual Payers' Guide
in
Payers' Guide
Iressa (Gefitinib), Oral Tyrosine Kinase Inhibitor, Approved for First-Line Therapy for Patients with Metastatic NSCLC and EGFR Mutation
Loretta Fala
March 2016, Vol 9, Seventh Annual Payers' Guide
in
Payers' Guide
Cotellic (Cobimetinib) FDA Approved as Part of a Combination for Patients with Advanced Melanoma and a BRAF Mutation
Loretta Fala
March 2016, Vol 9, Seventh Annual Payers' Guide
in
Payers' Guide
Alecensa (Alectinib), an Oral Tyrosine Kinase Inhibitor, Approved for Metastatic Non–Small-Cell Lung Cancer with ALK Mutation
Loretta Fala
March 2016, Vol 9, Seventh Annual Payers' Guide
in
Payers' Guide
Toujeo (Insulin Glargine) U-300 Approved to Improve Glycemic Control in Adults with Type 1 and Type 2 Diabetes
Loretta Fala
March 2016, Vol 9, Seventh Annual Payers' Guide
in
Payers' Guide
Finacia Foam (Azelaic Acid) the Newest Topical Treatment FDA Approved for the Treatment of Inflammatory Lesions of Rosacea
Loretta Fala
March 2016, Vol 9, Seventh Annual Payers' Guide
in
Payers' Guide
Cosentyx (Secukinumab): First IL-17A Antagonist Receives FDA Approval for Moderate-to-Severe Plaque Psoriasis
Loretta Fala
March 2016, Vol 9, Seventh Annual Payers' Guide
in
FDA Approvals
,
Payers' Guide
Corlanor (Ivabradine), First HCN Channel Blocker, FDA Approved for the Treatment of Patients with Heart Failure
Loretta Fala
March 2016, Vol 9, Seventh Annual Payers' Guide
in
FDA Approvals
,
Payers' Guide
Entresto (Sacubitril/Valsartan): First-in-Class Angiotensin Receptor Neprilysin Inhibitor FDA Approved for Heart Failure
Loretta Fala
March 2016, Vol 9, Seventh Annual Payers' Guide
in
FDA Approvals
,
Payers' Guide
Nucala (Mepolizumab): First IL-5 Antagonist Monoclonal Antibody FDA Approved for Maintenance Treatment of Patients with Severe Asthma
Loretta Fala
March 2016, Vol 9, Seventh Annual Payers' Guide
in
FDA Approvals
,
Payers' Guide
Portrazza (Necitumumab), an IgG1 Monoclonal Antibody, FDA Approved for Advanced Squamous Non–Small-Cell Lung Cancer
Loretta Fala
March 2016, Vol 9, Seventh Annual Payers' Guide
in
FDA Approvals
,
Payers' Guide
Repatha (Evolocumab): Second PCSK9 Inhibitor Approved by the FDA for Patients with Familial Hypercholesterolemia
Loretta Fala
March 2016, Vol 9, Seventh Annual Payers' Guide
in
FDA Approvals
,
Payers' Guide
Entresto (Sacubitril/Valsartan): First-in-Class Angiotensin Receptor Neprilysin Inhibitor FDA Approved for Patients with Heart Failure
Loretta Fala
September 2015 Vol 8, No 6
in
FDA Approvals
Lemtrada (Alemtuzumab) a New Treatment Option Approved by the FDA for the Treatment of Relapsing Forms of Multiple Sclerosis
Loretta Fala
Web Exclusives
in
FDA Approvals
Afrezza (Insulin Human) Inhalation Powder Approved for the Treatment of Patients with Type 1 or Type 2 Diabetes
Loretta Fala
March 2015, Vol 8, Sixth Annual Payers' Guide
in
Payers' Guide
,
FDA Approvals
Cyramza (Ramucirumab) Approved for the Treatment of Advanced Gastric Cancer and Metastatic Non–Small-Cell Lung Cancer
Loretta Fala
March 2015, Vol 8, Sixth Annual Payers' Guide
in
Payers' Guide
,
FDA Approvals
Invokamet (Canagliflozin plus Metformin HCl): First Fixed-Dose Combination with an SGLT2 Inhibitor Approved for the Treatment of Patients with Type 2 Diabetes
Loretta Fala
March 2015, Vol 8, Sixth Annual Payers' Guide
in
Payers' Guide
,
FDA Approvals
Jardiance (Empagliflozin), an SGLT2 Inhibitor, Receives FDA Approval for the Treatment of Patients with Type 2 Diabetes
Loretta Fala
March 2015, Vol 8, Sixth Annual Payers' Guide
in
Payers' Guide
,
FDA Approvals
Ofev (Nintedanib): First Tyrosine Kinase Inhibitor Approved for the Treatment of Patients with Idiopathic Pulmonary Fibrosis
Loretta Fala
March 2015, Vol 8, Sixth Annual Payers' Guide
in
Payers' Guide
,
FDA Approvals
Otezla (Apremilast), an Oral PDE-4 Inhibitor, Receives FDA Approval for the Treatment of Patients with Active Psoriatic Arthritis and Plaque Psoriasis
Loretta Fala
March 2015, Vol 8, Sixth Annual Payers' Guide
in
Payers' Guide
,
FDA Approvals
Sivextro (Tedizolid Phosphate) Approved for the Treatment of Adults with Acute Bacterial Skin and Skin- Structure Infections
Loretta Fala
March 2015, Vol 8, Sixth Annual Payers' Guide
in
Payers' Guide
,
FDA Approvals
Tanzeum (Albiglutide): A Once-Weekly GLP-1 Receptor Agonist Subcutaneous Injection Approved for the Treatment of Patients with Type 2 Diabetes
Loretta Fala
March 2015, Vol 8, Sixth Annual Payers' Guide
in
Payers' Guide
,
FDA Approvals
Trulicity (Dulaglutide): A New GLP-1 Receptor Agonist Once-Weekly Subcutaneous Injection Approved for the Treatment of Patients with Type 2 Diabetes
Loretta Fala
March 2015, Vol 8, Sixth Annual Payers' Guide
in
Payers' Guide
,
FDA Approvals
Zontivity (Vorapaxar), First-in-Class PAR-1 Antagonist, Receives FDA Approval for Risk Reduction of Heart Attack, Stroke, and Cardiovascular Death
Loretta Fala
March 2015, Vol 8, Sixth Annual Payers' Guide
in
Payers' Guide
,
FDA Approvals
Lenvima (Lenvatinib), a Multireceptor Tyrosine Kinase Inhibitor, Approved by the FDA for the Treatment of Patients with Differentiated Thyroid Cancer
Loretta Fala
March 2015, Vol 8, Sixth Annual Payers' Guide
in
Payers' Guide
,
FDA Approvals
Amitiza (Lubiprostone): The First Oral Treatment Approved by the FDA for Opioid-Induced Constipation
Loretta Fala
Special Feature Fifth Annual Payers' Guide to New FDA Approvals March 2014 Volume 7
in
Payers' Guide
Botox (OnabotulinumtoxinA) Now FDA Approved for Overactive Bladder
Loretta Fala
Special Feature Fifth Annual Payers' Guide to New FDA Approvals March 2014 Volume 7
in
Payers' Guide
Breo Ellipta (Fluticasone Furoate/Vilanterol): Fixed-Dose Combination Oral Inhaler Receives FDA Approval for Long-Term Maintenance Treatment of COPD
Loretta Fala
Special Feature Fifth Annual Payers' Guide to New FDA Approvals March 2014 Volume 7
in
Payers' Guide
Brintellix Tablets (Vortioxetine) Approved by the FDA for the Treatment of Major Depressive Disorder
Loretta Fala
Special Feature Fifth Annual Payers' Guide to New FDA Approvals March 2014 Volume 7
in
Payers' Guide
Fetzima Extended-Release (Levomilnacipran) Receives FDA Approval for the Treatment of Major Depressive Disorder in Adults
Loretta Fala
Special Feature Fifth Annual Payers' Guide to New FDA Approvals March 2014 Volume 7
in
Payers' Guide
Injectafer (Ferric Carboxymaltose Injection) Receives FDA Approval for the Treatment of Iron-Deficiency Anemia
Loretta Fala
Special Feature Fifth Annual Payers' Guide to New FDA Approvals March 2014 Volume 7
in
Payers' Guide
Invokana (Canagliflozin): First-in-Class SGLT2 Inhibitor Approved for the Treatment of Type 2 Diabetes
Loretta Fala
Special Feature Fifth Annual Payers' Guide to New FDA Approvals March 2014 Volume 7
in
Payers' Guide
Mirvaso (Brimonidine): First Topical Gel Approved by the FDA for the Treatment of Facial Erythema of Rosacea
Loretta Fala
Special Feature Fifth Annual Payers' Guide to New FDA Approvals March 2014 Volume 7
in
Payers' Guide
Latuda (Lurasidone HCl) Receives 2 New Indications for Use in Bipolar Depression as Monotherapy and as Adjunctive Therapy with Lithium or Valproate
Loretta Fala
Special Feature Fifth Annual Payers' Guide to New FDA Approvals March 2014 Volume 7
in
Payers' Guide
Nesina, Kazano, and Oseni: Three Alogliptin-Based Agents Approved for the Treatment of Type 2 Diabetes
Loretta Fala
Special Feature Fifth Annual Payers' Guide to New FDA Approvals March 2014 Volume 7
in
Payers' Guide
Simbrinza (Brinzolamide/Brimonidine Tartrate) Receives FDA Approval for the Treatment of Open-Angle Glaucoma or Ocular Hypertension
Loretta Fala
Special Feature Fifth Annual Payers' Guide to New FDA Approvals March 2014 Volume 7
in
Payers' Guide
Simponi (Golimumab) Receives New FDA Indication as the First Subcutaneous Anti-TNF Therapy for Ulcerative Colitis
Loretta Fala
Special Feature Fifth Annual Payers' Guide to New FDA Approvals March 2014 Volume 7
in
Payers' Guide
Simponi Aria (Golimumab): A New Intravenous TNF Inhibitor for the Treatment of Patients with Moderate-to-Severe Rheumatoid Arthritis
Loretta Fala
Special Feature Fifth Annual Payers' Guide to New FDA Approvals March 2014 Volume 7
in
Payers' Guide
Stelara (Ustekinumab) Receives New FDA Indication for the Treatment of Patients with Active Psoriatic Arthritis
Loretta Fala
Special Feature Fifth Annual Payers' Guide to New FDA Approvals March 2014 Volume 7
in
Payers' Guide
Tecfidera (Dimethyl Fumarate), a New Oral Therapy Approved by the FDA for the Treatment of Relapsing Forms of Multiple Sclerosis
Loretta Fala
Special Feature Fifth Annual Payers' Guide to New FDA Approvals March 2014 Volume 7
in
Payers' Guide
Xiaflex (Collagenase Clostridium Histolyticum), First Drug Approved by the FDA for Peyronie’s Disease
Loretta Fala
Special Feature Fifth Annual Payers' Guide to New FDA Approvals March 2014 Volume 7
in
Payers' Guide
Brintellix (Vortioxetine) Receives FDA Approval for the Treatment of Major Depressive Disorder
Loretta Fala
Web Exclusives
in
FDA Approvals
Injectafer (Ferric Carboxymaltose Injection) Receives FDA Approval for the Treatment of Iron-Deficiency Anemia
Loretta Fala
Web Exclusives
in
FDA Approvals
Fetzima Extended-Release Receives FDA Approval for the Treatment of Major Depressive Disorder in Adults
Loretta Fala
Web Exclusives
in
FDA Approvals
Simponi Aria: A New Intravenous TNF Inhibitor for the Treatment of Patients with Moderate-to-Severe Rheumatoid Arthritis
Loretta Fala
Web Exclusives
in
FDA Approvals
Mirvaso (Brimonidine): First Topical Gel Approved by the FDA for the Treatment of Facial Erythema of Rosacea
Loretta Fala
Payer Perspectives in Dermatology
in
Dermatology
Nesina, Kazano, and Oseni: Three Alogliptin-Based Agents Approved for the Treatment of Type 2 Diabetes
Loretta Fala
August 2013, Vol 6 ADA 2013 Highlights
in
FDA Approvals
Breo Ellipta: A Fixed-Dose Combination Oral Inhaler Receives FDA Approval for Long-Term Maintenance Treatment of COPD
Loretta Fala
Web Exclusives
in
FDA Approvals
Invokana (Canagliflozin): First-in-Class SGLT2 Inhibitor Approved for the Treatment of Type 2 Diabetes
Loretta Fala
Web Exclusives
in
FDA Approvals
Nesina, Kazano, and Oseni: Three Alogliptin-Based Agents Approved for the Treatment of Type 2 Diabetes
Loretta Fala
Web Exclusives
in
FDA Approvals
Simbrinza (Brinzolamide/Brimonidine Tartrate) Receives FDA Approval for the Treatment of Open-Angle Glaucoma or Ocular Hypertension
Loretta Fala
Web Exclusives
in
FDA Approvals
Zytiga Receives an Expanded Indication for Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer Before Chemotherapy
Loretta Fala
April 2013 Vol 6 No 3 Payers’ Guide to New FDA Approvals
in
Payers' Guide
,
FDA Approvals
Zioptan Receives FDA Approval for Patients with Open-Angle Glaucoma and/or Ocular Hypertension
Loretta Fala
April 2013 Vol 6 No 3 Payers’ Guide to New FDA Approvals
in
Payers' Guide
,
FDA Approvals
Qsymia: Combination Oral Therapy a New Weight-Loss Option for Obese or Overweight Patients
Loretta Fala
April 2013 Vol 6 No 3 Payers’ Guide to New FDA Approvals
in
Payers' Guide
,
FDA Approvals
Tudorza Pressair: A Novel Oral Inhalation Therapy for the Maintenance Treatment of Chronic Obstructive Pulmonary Disease–Associated Bronchospasm
Loretta Fala
April 2013 Vol 6 No 3 Payers’ Guide to New FDA Approvals
in
Payers' Guide
,
FDA Approvals
Vascepa: First EPA-Only Omega-3 Therapy Approved by the FDA for Severe Hypertriglyceridemia
Loretta Fala
April 2013 Vol 6 No 3 Payers’ Guide to New FDA Approvals
in
Payers' Guide
,
FDA Approvals
Eliquis Approved by the FDA to Reduce the Risks of Stroke and Systemic Embolism in Patients with Atrial Fibrillation
Loretta Fala
April 2013 Vol 6 No 3 Payers’ Guide to New FDA Approvals
in
Payers' Guide
,
FDA Approvals
Last modified: August 13, 2019
